CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year
CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...
eLife3d
Chromatin activity of IκBα mediates the exit from naïve pluripotency
This important study reveals a role for IκBα in the regulation of embryonic stem cell pluripotency. The solid data in mouse embryonic stem cells include separation of function mutations in IκBα to ...
ERS Genomics launches ‘Express License’ platform to democratise access to CRISPR/Cas9
The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...